Summary & Overview
CPT 0575U: HepatoTrack™ microRNA Test for Liver Allograft Rejection Risk
Headline: New PLA CPT code 0575U identifies a proprietary blood-based microRNA test for liver transplant rejection risk
Lead: CPT code 0575U designates HepatoTrack™, a proprietary laboratory molecular diagnostic that measures four microRNAs by RT–PCR to generate a risk score for liver allograft rejection. The code standardizes billing for a single-manufacturer assay with implications for transplant care pathways and payer coverage decisions.
What this code represents and why it matters: CPT code 0575U is a PLA code tied to a unique commercial test for assessing liver transplant rejection risk noninvasively. Nationally, PLA codes clarify billing for novel diagnostics, affect prior authorization and coverage policies, and influence how labs and transplant programs document and price specialized testing.
Key payers covered: This analysis addresses national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks and clinical context for CPT code 0575U, explains the test methodology (RT–PCR measurement of miR–122, miR–885, miR–23a, and a spike–in control), and outlines considerations for payer coverage and coding workflows. It summarizes where the test is performed and how the PLA designation limits the code to a single manufacturer's assay. The report also highlights implications for transplant programs, laboratory billing, and clinical documentation.
Note: Data not available in the input are identified where applicable.
Billing Code Overview
CPT code 0575U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to a single commercial laboratory test: HepatoTrack™ from LuminoDx Laboratory, LuminoDx Inc. The assay evaluates the risk of liver allograft (transplant) rejection by measuring expression of four microRNA genes in a blood sample. Using reverse transcription polymerase chain reaction (RT–PCR), the test quantifies miR–122, miR–885, a housekeeping gene miR–23a, and a spike–in control to generate a risk score for rejection.
Service Type: Laboratory molecular diagnostic assay (PLA)
Typical Site of Service: Clinical laboratory or specialty reference laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 54-year-old male liver transplant recipient presents for routine post-transplant surveillance with recent abnormalities in liver function tests and intermittent low-grade fevers. The transplant hepatologist orders HepatoTrack™ (LuminoDx Laboratory) to assess risk of allograft rejection by measuring expression of four microRNAs in peripheral blood. A phlebotomy appointment is scheduled at an outpatient infusion center or clinical laboratory. A whole-blood sample is collected into the tube specified by the manufacturer, labeled with patient and order identifiers, and shipped to LuminoDx Laboratory under required temperature and chain-of-custody conditions. The laboratory performs reverse transcription polymerase chain reaction (RT–PCR) measuring miR-122, miR-885, miR-23a (housekeeping gene), and a spike-in control, calculates a composite risk score, and reports a result to the ordering transplant hepatologist and transplant surgery team. Typical sites of service include outpatient hospital laboratories, independent commercial reference laboratories, and hospital outpatient infusion or transplant clinics. Common clinical use cases include surveillance for subclinical rejection, evaluation of unexplained LFT elevations, and monitoring during immunosuppression adjustment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |